Autonomix Medical, Inc.
Business
Autonomix Medical, Inc. is a development-stage medical device company advancing a catheter-based, microchip-enabled sensing platform to detect and differentiate peripheral neural signals and enable targeted transvascular treatment. Its main offerings include a high-sensitivity sensing catheter with onboard microchip processing, radiofrequency (RF) ablation catheters, disposable handpieces and supporting software intended to sense, ablate and confirm nerve treatment. The company’s business is organized around diagnostic sensing and therapeutic RF ablation efforts, with plans to combine both into an integrated device and to leverage its patent portfolio. Autonomix targets hospital catheter labs and interventional radiology channels, pursuing clinical trials in Europe and regulatory pathways in the U.S. for commercialization to address pancreatic cancer pain and other peripheral nerve disorders globally.
Summary from filing dated 2025-05-29
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 |
|---|---|---|---|---|---|
| Research and development | 7 | 5 | 2 | 745,000 | |
| General and administrative | 10 | 7 | 5 | 1 | |
| Total operating expenses | 17 | 12 | 12 | 2 | |
| Loss from operations | −17 | −12 | −12 | −2 | |
| Interest expense | 0 | −176,000 | −79,000 | 0 | |
| Interest income | 319,000 | 354,000 | 127,000 | 0 | |
| Total other income, net | 319,000 | 178,000 | −3 | 0 | |
| Loss before income taxes | −17 | −11 | −15 | −2 | |
| Income taxes | 0 | 0 | 0 | 0 | |
| Net loss | −17 | −11 | −15 | −2 | |
| Loss per share - basic and diluted (in dollars per share) | −2.32 | −6.46 | −14.82 | −0.17 | |
| Weighted average shares outstanding - basic and diluted (in shares) | 7 | 2 | 1 | 12 |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 9 | 9 | 865,000 | — | |
| Other current assets | 577,000 | 473,000 | 783,000 | 0 | — | |
| Total current assets | 8 | 10 | 9 | 865,000 | — | |
| Property and equipment, net | 19,000 | 21,000 | 16,000 | 0 | — | |
| Deferred offering costs | 0 | 176,000 | 0 | — | — | |
| Total noncurrent assets | 19,000 | 197,000 | 16,000 | 0 | — | |
| Total Assets | 8 | 10 | 9 | 865,000 | — | |
| Accounts payable | 700,000 | 676,000 | 492,000 | 173,000 | — | |
| Accrued expenses | 1 | 1 | 285,000 | 48,000 | — | |
| Total current liabilities | 2 | 2 | 777,000 | 221,000 | — | |
| Total Liabilities | 2 | 2 | 2 | 221,000 | — | |
| Commitments and contingencies (Note 4) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and 2025, respectively | 0 | 0 | 0 | 0 | — | |
| Common stock, $0.001 par value, 500,000,000 shares authorized, 11,409,344 and 2,497,033 shares issued and outstanding as of March 31, 2026 and 2025, respectively | 11,000 | 2,000 | 1,000 | 12,000 | — | |
| Additional paid-in capital | 73 | 58 | 47 | 24 | — | |
| Accumulated deficit | −67 | −50 | −39 | −24 | — | |
| Total Stockholders' Equity | 6 | 8 | 8 | 644,000 | 2 | |
| Total Liabilities and Stockholders' Equity | 8 | 10 | 9 | 865,000 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 |
|---|---|---|---|---|---|
| Stock-based compensation | 529,000 | 2 | 618,000 | 0 | |
| Stock option cancellations | 4 | 0 | — | — | |
| Issuance of common stock for equity line of credit commitment fee | 267,000 | 0 | — | — | |
| Depreciation and amortization expense | 12,000 | 183,000 | 81,000 | 0 | |
| Issuance of common stock, net of discount for lack of marketability | 0 | 101,000 | — | — | |
| Other current assets | −104,000 | 310,000 | −478,000 | 9,000 | |
| Accounts payable | 24,000 | 184,000 | 320,000 | 81,000 | |
| Accrued expenses | −27,000 | 746,000 | 237,000 | 46,000 | |
| Net cash used in operating activities | −12 | −8 | −7 | −2 | |
| Purchase of property and equipment | −10,000 | −14,000 | −19,000 | 0 | |
| Net cash used in investing activities | −10,000 | −14,000 | −19,000 | 0 | |
| Gross proceeds from issuance of common stock | 4 | 0 | — | — | |
| Direct financing costs for issuance of common stock | −141,000 | 0 | — | — | |
| Gross proceeds from warrant inducement | 3 | 0 | — | — | |
| Direct transaction costs for warrant inducement | −291,000 | 0 | — | — | |
| Gross proceeds from issuance and exercises of pre-funded warrants | 5 | 0 | — | — | |
| Direct financing costs for issuance of pre-funded warrants | −485,000 | 0 | — | — | |
| Gross proceeds from issuance of common stock, pre-funded and common warrants | 0 | 10 | — | — | |
| Direct transaction costs for issuance of common stock, pre-funded and common warrants | 0 | −1 | — | — | |
| Payment of issuance costs for registration statement | 0 | −176,000 | — | — | |
| Gross proceeds from exercise of warrants | 0 | 1,000 | — | — | |
| Proceeds from sales of common stock | 0 | 2,000 | 3 | 675,000 | |
| Net cash provided by financing activities | 10 | 9 | 14 | 675,000 | |
| Net change in cash and cash equivalents | −2 | 528,000 | 8 | −1 | |
| Recognition of deferred financing costs associated with issuance of common stock | −176,000 | 0 | — | — | |
| Proceeds from cashless exercise of warrants | 1,000 | 39,000 | 2,000 | 0 | |
| Warrants issued for equity issuance costs | 0 | 479,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Autonomix Medical, Inc.'s CIK number?
Autonomix Medical, Inc.'s SEC CIK number is 0001617867 (1617867). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Autonomix Medical, Inc.'s SEC filings?
All of Autonomix Medical, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Autonomix Medical, Inc. last report earnings?
Autonomix Medical, Inc. (AMIX) most recently filed an earnings 8-K with the SEC on Feb 13, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-25-003673). This is Autonomix Medical, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Autonomix Medical, Inc.'s most recent earnings 8-K?
Autonomix Medical, Inc.'s latest earnings 8-K (Item 2.02) was filed Feb 13, 2025 under accession 0001437749-25-003673. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Autonomix Medical, Inc.'s latest earnings 8-K →
Look up any company's CIK number →